Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survivalLeonie K. de Klerk, Adam J. Bass, Jérémy Augustin et al.|Journal for ImmunoTherapy of Cancer|2021Cited by 30
FOLFOX plus ziv‐aflibercept or placebo in first‐line metastatic esophagogastric adenocarcinoma: A double‐blind, randomized, multicenter phase 2 trialJames M. Cleary, Peter C. Enzinger, Nora Horick et al.|Cancer|2019Cited by 24